| NCT ID | NCT07278778 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Pediatric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-02-04 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-02-04 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study invites parents of children with cancer to use an electronic health record (EHR)-based communication tool, called the Cancer Care Companion, and assess the acceptability, appropriateness, and feasibility of the tool.
Eligibility Criteria
Eligibility Criteria for Parents: Parents of children with cancer will be enrolled if they meet the following criteria: * They are a legal guardian of a child diagnosed with cancer in the prior 4 weeks. * The child plans to receive or currently receives cancer directed therapy at St. Louis Children's Hospital. * The parent or legal guardian has access to internet through a computer or smart phone. * Speaks and reads in English * The parent or legal guardian agrees to enroll in Epic MyChart to access a proxy portal for their child. Eligibility Criteria for Clinicians: * Clinicians with patients who have parents participating may be enrolled. Clinician participants will be employed at SLCH or Washington University School of Medicine (WUSM). The clinicians will include physicians, nurse practitioners, and nurse coordinators from the leukemia/lymphoma, brain tumor, and solid tumor teams in order to represent the breadth of pediatric cancer diagnoses.
Contact & Investigator
Bryan A Sisk, MD, MSCI
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT07278778 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pediatric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07278778 currently recruiting?
Yes, NCT07278778 is actively recruiting participants. Contact the research team at siskb@wustl.edu for enrollment information.
Where is the NCT07278778 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT07278778 clinical trial?
NCT07278778 is sponsored by Washington University School of Medicine. The principal investigator is Bryan A Sisk, MD, MSCI at Washington University School of Medicine. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.